CTT PHARMACEUTICAL HOLDINGS, INC. purchased $500 of CTTH
CTT PHARMACEUTICAL HOLDINGS, INC. (CEO) purchased 7,700 shares of CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) at $0.06 on 2026-08-07.
How this was made
The 30-second read
Why it matters
The CEO’s open-market purchase is a positive sentiment datapoint but is unlikely to change valuation materially given the small transaction size and lack of accompanying company-specific news.
Market read
Traders may note insider buying, but the disclosed $500.50 value is too small to be a standalone catalyst.
What to watch
No 10b5-1 plan is cited, but the filing does not provide intent, timing constraints, or whether other insiders are buying or selling.
Background
The article is an SEC Form 4 insider transaction disclosure for CTT Pharmaceutical Holdings, Inc. (CTTH).
Ticker impact
CTTH CEO filed a Form 4 open-market purchase of 7,700 shares at $0.0650/share, totaling $500.50, dated 2026-08-07.
Likely negligible to modest positive drift, but size is too small to drive a sustained repricing.
The disclosure is primary-source (Form 4) but the transaction value is only about $500, which typically has limited market-moving power versus earnings, guidance, or material corporate events.
Market effects
No sector-level signal; this is a routine insider transaction with no stated operational or regulatory catalyst.
None indicated.
None indicated.
Counterpoint
The buy may be routine compensation-related or opportunistic at low price levels, and the small dollar amount reduces interpretability.
Key entities
- issuerCTT Pharmaceutical Holdings, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderCTTH CEO
Reported as the officer executing the open-market purchase.